Equity Overview
Price & Market Data
Price: $7.50
Daily Change: +$0.04 / 0.53%
Range: $7.50 - $7.65
Market Cap: $284,929,472
Volume: 549
Performance Metrics
1 Week: 19.94%
1 Month: 14.50%
3 Months: -2.74%
6 Months: -18.02%
1 Year: -30.86%
YTD: -2.86%
Company Details
Employees: 173
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.